ARIA News Alert Ariad Pharmaceuticals (ARIA) 6.08 12/16/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Ariad Pharmaceuticals (ARIA) 6.08 $ARIA

Does George Soros Think Biotech's Bull Run Is Finally Coming to an End?
George Budwell, The Motley Fool - Motley Fool - Mon Dec 15, 6:45AM CST
To say that biotech stocks have performed well as a group over the last two years is an understatement; they have absolutely crushed the broader markets. For example, the iShares Nasdaq Biotech Index has more than tripled the performance of the ...
SRPT: 12.60 (-0.40), IBB: 293.67 (-3.99), ARIA: 6.08 (-0.02), CELG: 110.09 (-1.79)

SmarTrend Watching for Potential Rebound in Shares of Ariad Pharmaceuticals After 7.76% Loss
Comtex SmarTrend(R) - Thu Dec 11, 4:40PM CST
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $6.34 to a high of $6.88. Yesterday, the shares fell 7.8%, which took the trading range below the 3-day low of $6.80 on volume of 13.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ARIA: 6.08 (-0.02)

Energy Stocks Pare Gains as Crude Oil Closes Below $60 For First Time in Five Years
at The Street - Thu Dec 11, 1:52PM CST
Energy stocks are leading the markets higher, a day after they sparked a selloff.
SPLS: 17.25 (+0.40), DAL: 45.38 (-2.42), XOM: 86.41 (-0.49), COP: 63.22 (+1.53), LLY: 69.26 (-0.41), LULU: 52.50 (-1.37), LUV: 39.58 (-2.00), URBN: 32.63 (+0.16), EBAY: 55.94 (+0.50), AAL: 47.96 (-2.88), ODP: 7.92 (+0.08), ARIA: 6.08 (-0.02), CVX: 101.70 (+0.84), WAG: 72.39 (-1.05), XLE: 74.01 (+0.65)

Nasdaq stocks posting largest percentage decreases
AP - Thu Dec 11, 12:19PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
AMBA: 45.78 (-0.35), LNCO: 10.87 (+1.71), MCEP: 6.16 (+0.66), LAKE: 9.19 (-0.46), CLDN: 17.76 (+0.03), BRID: 7.54 (+0.04), ARIA: 6.08 (-0.02), LINE: 12.54 (+2.71), MIND: 5.82 (+0.13), DGLY: 14.38 (+0.34), ALLT: 8.48 (-0.04), ROSE: 18.39 (+1.18)

Ariad slumps after analyst downgrade
Seeking Alpha - at Seeking Alpha - Thu Dec 11, 9:25AM CST

IBB: 293.67 (-3.99), ARIA: 6.08 (-0.02)

Will Ariad Pharmaceuticals (ARIA) Stock be Affected Today by This Analyst Action?
at The Street - Thu Dec 11, 8:14AM CST
Shares of Ariad Pharmaceuticals (ARIA) are down after Credit Suisse downgraded the global oncology company to 'underperform' from 'neutral' and lowered its price target to $6 from $8.
ARIA: 6.08 (-0.02)

Downgrade Alert for Ariad Pharmaceuticals (ARIA)
Comtex SmarTrend(R) - Thu Dec 11, 6:54AM CST
Ariad Pharmaceuticals (NASDAQ:ARIA) was downgraded from Neutral to Underperform at Credit Suisse today. The stock closed yesterday at $7.02 on volume of 4.6 million shares, below average daily volume of 6.3 million. In the past 52 weeks, Ariad Pharmaceuticals share prices have been bracketed by a low of $3.80 and a high of $9.83 and closed yesterday at $7.02, 85% above that low price. Over the last five market days, the 200-day moving average (MA) has gone down 0.3% while the 50-day MA has advanced 1.5%.
ARIA: 6.08 (-0.02)

Uptrend Call Working As Ariad Pharmaceuticals Stock Rises 22.6% (ARIA)
Comtex SmarTrend(R) - Tue Dec 09, 5:08PM CST
SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on October 29th, 2014 at $5.92. In approximately 1 month, Ariad Pharmaceuticals has returned 22.57% as of today's recent price of $7.25.
ARIA: 6.08 (-0.02)

Long-term follow up data for Iclusig positive
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 9:54AM CST

ARIA: 6.08 (-0.02)

ARIAD Announces Follow-up Data from Phase 1 and PACE Trials of Ponatinib in Patients with T315I Mutation in Chronic Myeloid Leukemia
Business Wire - Tue Dec 09, 6:35AM CST
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced safety and efficacy follow-up data on Iclusig(R) (ponatinib), its approved BCR-ABL inhibitor, in patients with a baseline T315I mutation from its Phase 1 and Phase 2 PACE trials in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
ARIA: 6.08 (-0.02)

ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib in Chronic-Phase Chronic Myeloid Leukemia from Phase 1 Clinical Trial
Business Wire - Tue Dec 09, 6:35AM CST
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced long-term follow up data from the Phase 1 trial of Iclusig(R) (ponatinib), its approved BCR-ABL inhibitor, in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The study now shows that with a median follow-up of four years in chronic phase CML (CP-CML) patients, Iclusig continues to demonstrate anti-leukemic activity in patients with limited treatment options and that responses have been maintained in CP-CML patients (n=43) with 72 percent having a major cytogenetic response (MCyR), 65 percent having a complete cytogenetic response (CCyR) and 56 percent having a major molecular response (MMR). Long-term safety data show that careful benefit-risk evaluations should guide decisions to use and maintain ponatinib therapy, particularly in patients who may be at increased risk for arterial thrombotic events.
ARIA: 6.08 (-0.02)

ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial
Business Wire - Mon Dec 08, 6:35AM CST
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced long-term follow up from its pivotal Phase 2 trial of Iclusig(R) (ponatinib), its approved BCR-ABL inhibitor, in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The study now shows that with a median follow-up of approximately 3 years for chronic-phase CML (CP-CML) patients in the trial, Iclusig continues to demonstrate anti-leukemic activity in patients with limited treatment options. Deep and durable responses have been maintained in CP-CML patients with 83 percent of CP-CML patients who achieved a response, estimated to remain in major cytogenetic response (MCyR) at three years.
ARIA: 6.08 (-0.02)

Why Ariad Pharmaceuticals, Inc. Stock Catapulted 19% Higher in November
Sean Williams, The Motley Fool - Motley Fool - Fri Dec 05, 7:36AM CST
ARIA data by YCharts What: Shares of Ariad Pharmaceuticals , a biopharmaceutical company focused on developing therapies to treat cancer, surged by 19% in November according to data from S&P Capital IQ after reporting market-topping...
ARIA: 6.08 (-0.02)

ARIAD Pharmaceuticals (ARIA) Is Strong On High Volume Today
at The Street - Tue Dec 02, 9:00AM CST
Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a strong on high relative volume candidate
ARIA: 6.08 (-0.02)

Vargatef cleared in Europe for lung cancer
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 8:23AM CST

HTBX: 4.00 (-0.08), BIB: 118.31 (-2.94), INCY: 71.62 (-0.52), PFE: 30.67 (-0.19), IBB: 293.67 (-3.99), DRGS: 52.00 (unch), BIND: 5.56 (+0.01), BMY: 57.69 (-0.86), GSK: 41.92 (+0.62), ONTY: 1.76 (-0.14), ECYT: 5.88 (-0.16), BIS: 50.05 (+1.20), CLVS: 53.28 (+0.09), AZN: 69.56 (-0.18), MRK: 56.80 (-0.15), ARIA: 6.08 (-0.02), IRY: 46.98 (+0.45), IXJ: 99.16 (-0.64), FPRX: 21.92 (+0.07)

Most active Nasdaq-traded stocks
AP - Tue Nov 25, 5:58PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
MU: 32.92 (-0.43), GILD: 100.46 (-2.70), FB: 74.69 (-2.30), CMCSK: 54.53 (-0.18), ARIA: 6.08 (-0.02), ARCP: 7.70 (-0.53), MSFT: 45.16 (-1.51), INTC: 35.56 (-0.36), CMCSA: 54.81 (-0.13), AAPL: 106.75 (-1.47), CSCO: 26.58 (-0.10)

Ariad Pharmaceuticals (ARIA) Jumps: Stock Gains 9.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 25, 8:25AM CST
Ariad Pharmaceuticals (ARIA) was a big mover last session, as the company saw its shares rise nearly 10% on the day.
LCI: 42.70 (-1.35), VRX: 136.92 (-1.24), SCMP: 12.89 (+0.23), ARIA: 6.08 (-0.02)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Alliance for Women in Media Champions Change in 2026

Updated Category News Views 87

A Celebration of Trailblazing Women in Media If there's one thing I've learned about strong leadership, it's that you can't fake authenticity. Today, we're tipping our hats to some genuine trailblazers. The Alliance for Women in Media (AWM) held its annual Gracies Leadership Awards, celebrating the achievements and vision of seven remarkable women. Honoring the...

Continue Reading
Paris Baguette Expands U.S. Presence with New Georgia Café

Updated Category News Views 141

Café Culture Meets Expansion Chase You ever sip a cup of coffee and hear the rustle of opportunity in the steam? That's what's brewing at Paris Baguette with their new opening in Peachtree Corners, Georgia. This isn't just another café setting up shop; it's part of a larger scheme—expanding their sweet slice of the global market pie. Paris Baguette's Georgia Gamble...

Continue Reading
Vipshop Prepares for Q3 Financial Results Release

Updated Category News Views 93

Countdown to Vipshop's Third Quarter Results November 24th might just be another day on the calendar for some, but for those of us keeping tabs on the markets, it's a make-or-break moment for Vipshop Holdings Limited. The off-price retail titan from China, trailing under the ticker NYSE:VIPS, is gearing up to swing the doors wide open on its third-quarter financial...

Continue Reading
Mars Moves on Cash Tender Offers for Seniors' Notes

Updated Category News Views 104

A Strategic Financial Maneuver or a Casual Gambit? Okay, what’s Mars up to now, you ask? Here we go with this. The behemoth behind some of your favorite snacks and pet indulgences is making waves—not with candy, but with cash. Mars, Incorporated is rolling out tender offers to buy back a substantial chunk of its Senior Notes for $2 billion in cold, hard cash. When a...

Continue Reading
Gold Tumbles: Kinross Faces Class Action Lawsuit

Updated Category News Views 120

Digging Deep into Kinross's Legal Fallout Well, here's a doozy for those investing in the precious metal market. Kinross Gold Corporation (NYSE: KGC) finds itself knee-deep in legal muck. Investors who bought into the Canadian gold miner's promises might be scrambling, as a class action lawsuit has just been lobbed their way. The culprit? A hefty drop-off in their...

Continue Reading
Ozelle Unveils AI-Powered Hematology Tool at MEDICA 2026

Updated Category News Views 124

Pioneering a New Era in Hematology In the fast-paced world of blood analysis, standing still means being left in the dust. Ozelle, with its AI-powered innovative tool, is making waves at MEDICA 2026 in Düsseldorf. Meet O-Cyte 1, an automated hematology analyzer that's merging high-resolution cell imaging with routine CBC (Complete Blood Count) testing. Sounds like...

Continue Reading
Older Adults Embrace Cosmetic Dentistry for Confidence

Updated Category News Views 61

Why the Shift to Cosmetic Dentistry Later in Life? Aging doesn't just wrinkle your skin; it affects your smile too. Dr. Joseph T. Sumrall and Dr. Gran Sumrall, the dental gurus of Warner Robins, Georgia, are laying out why more adults are jumping on the cosmetic dentistry bandwagon as they age. Spoiler: It ain't about getting a movie-star grin but something much deeper....

Continue Reading
Lear Gears Up for Goldman Sachs Event Spotlight

Updated Category News Views 23

Lear Prepares for the Big Stage in London Autumn leaves and industry insights are falling in full swing as Lear Corporation gets its ducks in a row for the upcoming Goldman Sachs 18th Annual Industrials & Autos Week. Kicking off on December 3, 2026, this gathering in London isn't just another checkbox on their corporate calendar—it's a prime moment in the spotlight....

Continue Reading
Cheyenne Real Estate: Neighborhood Nuances and Choices

Updated Category News Views 128

Unearthing the Hidden Dynamics of Cheyenne's Real Estate You've got this picturesque vision in your head of Cheyenne, Wyoming—a sprawling cowboy town with its wild winds and wide-open spaces. But if you think all those neighborhoods are cut from the same cloth, you've got another thing coming. The real estate scene here is just as varied as the prairies stretching out...

Continue Reading
Gwen Stefani Kicks Off OCVIBE's New Concert Hall

Updated Category News Views 199

A Homecoming Steeped in Nostalgia Orange County’s about to do a serious throwback, folks! Gwen Stefani is set to headline the opening concert at OCVIBE's spanking new concert hall in Anaheim on March 17, 2027. Curious choice for their opener? Hardly. This gal's practically woven into the county’s tapestry—her roots run deep here, enough to make even the casual music...

Continue Reading

Top 5 Most Recently Viewed Articles

Formula Wellness Scores Top 50 Position from Allergan

Updated Category News Views 15

Pushing Boundaries in Aesthetic and Wellness Here's something you don't see every day: Formula Wellness just landed Top 50 status for 2026 from Allergan Aesthetics, the same folks who brought Botox to the world. It’s no small feat, and if you've been keeping an eye on sectors blending wellness with aesthetics, this might be the story to watch. Formula Wellness isn't...

Continue Reading
iTeos Therapeutics Showcases Inupadenant Trial Insights at ESMO

Updated Category News Views 98

Introduction to iTeos Therapeutics and ESMO Congress iTeos Therapeutics, Inc. (NASDAQ: ITOS), based in Watertown, Mass. and Gosselies, Belgium, is making strides in the field of biopharmaceuticals. Their mission focuses on pioneering a new wave of immuno-oncology therapies aimed at fighting cancer. The excitement around their innovative approaches is palpable, especially...

Continue Reading
Plastic vs. Metal Parts: The Manufacturing Showdown

Updated Category News Views 65

Understanding the Material Dilemma In manufacturing, a pivotal choice emerges early on: plastic or metal? It's a game-changer in product development, according to Ryan Eggleston from UTP Solutions. The stakes are high because picking the right material can define the success—or failure—of a product design. The Rise of Plastics Plastics have carved out a strong niche...

Continue Reading
Fast Debt Recovery Specialist Sets New Standards in Compliance

Updated Category News Views 105

Fast Debt Recovery Specialist Earns Newly Required License Fast Debt Recovery Specialist has marked a major milestone, becoming one of the first firms in Singapore to secure the government’s newly required debt collection license. It’s a clear signal: the agency intends to operate squarely within the law while holding fast to ethical, transparent recovery practices....

Continue Reading
Rivian's 2024 Performance: Impressive Production and Delivery Stats

Updated Category News Views 327

Rivian Announces Strong Production and Delivery Figures for 2024 Rivian Automotive, Inc. (NASDAQ: RIVN), a leading player in the electric vehicle market, has revealed its impressive production and delivery totals for 2024. The company successfully produced a remarkable 12,727 vehicles in the fourth quarter alone, rounding off a total annual production of 49,476 vehicles....

Continue Reading